Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small interfering RNA |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2022 |
| gptkbp:ATCCode |
N07XX18
|
| gptkbp:brand |
gptkb:Amvuttra
|
| gptkbp:CASNumber |
2228296-18-6
|
| gptkbp:chemicalFormula |
C384H491F12N171O260P39S39
|
| gptkbp:developer |
gptkb:Alnylam_Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
vutrisiran
|
| gptkbp:indication |
polyneuropathy of hereditary transthyretin-mediated amyloidosis
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits transthyretin (TTR) synthesis
|
| gptkbp:pregnancyCategory |
not assigned
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
injection site reaction
shortness of breath elevated liver enzymes arthralgia pain in extremity |
| gptkbp:target |
gptkb:transthyretin_mRNA
|
| gptkbp:UNII |
1J8A1Q1K6T
|
| gptkbp:usedFor |
treatment of hereditary transthyretin-mediated amyloidosis
|
| gptkbp:bfsParent |
gptkb:Amvuttra
|
| gptkbp:bfsLayer |
7
|